EU nod for Astellas's Modigraf for transplant rejection
This article was originally published in Scrip
Executive Summary
The EU's CHMP has adopted a positive opinion on Astellas' oral suspension formulation of its immunosuppressive drug tacrolimus (Modigraf) for the prophylaxis of transplant rejection in kidney, liver or heart allograft recipients, and treatment of allograft rejection resistant to treatment with other immunosuppressive products in adult and paediatric patients.